Myeloproliferative Neoplasms

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

David P. Steensma, MD, discusses some new data in myelodysplastic syndromes and ongoing research in the space.

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.